Verifying Clearance...
Definium Therapeutics' LSD-Based Drug Shows Promise in Mid-Stage Trial, Stocks Surge
RT by ZeroHedge News: Shares of Definium Therapeutics experienced a remarkable surge following the announcement that its psychedelic drug DT120 achieved key goals in late-stage clinical trials aimed at treating major depressive disorder. The positive results could signify a shift in the acceptance and approval of psychedelic treatments in mainstream medicine, particularly with supportive regulatory developments.
This story is using an image pulled from the original reporting.
Story change
Correction: Facts updated
Before: Signal intercept: Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal. Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal Definium Therapeutics shares surged as much as 54% on Monday, reaching $37.90 in m
Why it changed: The old body refers to the drug as a general LSD-based depression drug, while the new body specifies the drug as DT120, which is a specific name for the treatment being tested.
Now: SHRED REPORT The unfolding narrative around psychedelic medicine has gained momentum as Definium Therapeutics reports significant progress in its clinical trials for a new LSD-based treatment targeting major depression. The implications of th
READ NEXT
Recommended Intelligence
Looking for the best next stories...
No comments yet. Start the conversation.